IOncology

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcases the latest research findings, clinical practices, treatment advancements, and technological innovations in breast cancer from the past year.

Breast cancer remains a leading malignancy threatening women’s health, and optimizing treatment strategies continues to be a major focus of research. Neoadjuvant therapy, especially for HER2-positive breast cancer, plays a key role in improving survival outcomes and quality of life. The 47th San Antonio Breast Cancer Symposium (SABCS) will take place from December 10 to 13, 2024, in San Antonio, Texas. Professor Wenbin Zhou and his team from Jiangsu Province Hospital will present a study (Poster Abstract No: P3-11-24) evaluating the efficacy of pyrotinib combined with trastuzumab and nab-paclitaxel in HER2-positive breast cancer. The results demonstrate an impressive pathological complete response (tpCR) rate in HER2-enriched patients, with good tolerability and controllable safety. This innovative therapy offers new hope for HER2-positive breast cancer patients and supports precision treatment strategies.

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. A phase II prospective study led by Professors Huiping Li and Hanfang Jiang from Peking University Cancer Hospital will be presented as a poster (Abstract No: P1-02-12). This study explores the efficacy and safety of hetrombopag monotherapy in treating cancer therapy-induced thrombocytopenia (CTIT) in breast cancer patients. Preliminary findings show that hetrombopag achieves a high treatment response rate, rapidly improves platelet (PLT) levels, and demonstrates excellent efficacy and tolerance without severe adverse events, particularly no thrombosis. These results confirm the potential of hetrombopag as a novel therapeutic option for CTIT in breast cancer patients, providing new evidence-based data. As the research progresses, hetrombopag is expected to play a greater role in improving treatment outcomes for breast cancer patients undergoing antitumor therapy.

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, Texas, USA. As the largest and most influential breast cancer-focused academic meeting globally, the conference will unveil a series of groundbreaking research findings. A study conducted by Dr. Hui Xie and her team from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)was selected for poster presentation (Abstract No: P3-01-19). The research employs proteomics to explore the degradomic characteristics of mammary tumor-adjacent adipocytes, revealing that the peptide MASP6 promotes breast cancer invasion and metastasis and may serve as a personalized biomarker and therapeutic target. This article provides an overview of the study.

The thoracic oncology session at the 2024 ESMO Asia Annual Meeting featured prominent oral presentations, focusing on thymic tumors and non-small cell lung cancer (NSCLC). Key studies included the Phase II MARBLE trial (Abstract LBA8) evaluating atezolizumab combined with carboplatin/paclitaxel for metastatic or recurrent thymic carcinoma and the Phase II AL3810-202 trial (Abstract 6250) assessing Lucitanib (Delitinib, AL3810) as a second-line or subsequent therapy for advanced recurrent or metastatic thymic carcinoma.

Previous studies have demonstrated that short-term efficacy metrics, such as objective response rate (ORR), are associated with long-term survival outcomes, such as overall survival (OS), in targeted therapy for advanced hepatocellular carcinoma (HCC). At the 2024 International Liver Cancer Association (ILCA) Conference, Professor Masatoshi Kudo from Kinki University Faculty of Medicine in Japan presented exploratory analyses on the correlation between efficacy metrics like depth of response (DpR) and duration of response (DoR) with OS benefits. He also discussed their value in guiding systemic drug therapy combined with local treatments. We interviewed Professor Kudo to share his key findings.

The 2024 European Society for Medical Oncology Asia Congress (ESMO Asia 2024) was held in Singapore from December 6 to 8. In the session featuring selected oral presentations on thoracic oncology, Professor  Wentao Fang from Shanghai East Hospital, Tongji University presented findings from the AL3810-202 trial (Abstract 625O), which evaluated Lucitanib (Delitinib, AL3810) as a second-line or subsequent therapy for advanced recurrent or metastatic thymic carcinoma. During the conference, Oncology Frontier invited Professor Fang to discuss the study findings and share highlights from the event.

The European Society for Medical Oncology Asia (ESMO Asia) Congress was held in Singapore，from 6 to 8 December 2024. ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region, providing a remarkable platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field. During the three-day event, Qilu Pharmaceutical unveiled the latest findings from three key studies on iparomlimab and tuvonralimab (QL1706), a bifunctional MabPair® product of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.

With the continuous progress in the field of breast cancer treatment, precision medicine is gradually becoming the key to improving treatment outcomes. At the 2024 ESMO ASIA Annual Meeting, Prof. Biyun Wang from Fudan University Shanghai Cancer Center delivered a proffered oral presentation in the "Proffered Paper session: Breast cancer" session, introducing to colleagues around the world the latest research findings of her team in screening and guiding first-line treatment of HR+/HER2- metastatic breast cancer with 18F-FES PET/CT. After the presentation, Oncology Frontier specially invited Professor Wang Biyun for an interview. She provided us with a detailed interpretation of the background, significance, challenges, and innovation points of this study, and also looked forward to the research directions in the field of HR+/HER2- breast cancer treatment in the future, hoping to provide valuable references and inspiration for the majority of clinicians and researchers.